Microrna in combination with her2-targeting drugs reduces breast cancer cell viability in vitro

HIGHLIGHTS

• who: Lisa Svartdal Normann from the DepartmentUniversity Hospital have published the research: MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro, in the Journal: Scientific Reports Scientific Reports
• what: The authors aim to explore whether miRNAs may sensitize cancer cells to HER2-targeted treatment. Hits from the screen were explored and the authors here present the most relevant miRNAs to include in combinatorial treatment with trastuzumab and lapatinib.
• how: To examine which pathways the miRNAs with altered expression may be relevant for the authors identified predicted mRNA targets . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.